Pliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on Monday

Pliant Therapeutics (NASDAQ:PLRX) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Pliant Therapeutics to post earnings of ($0.44) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Pliant Therapeutics Trading Down 4.6%

PLRX opened at $1.24 on Monday. The firm has a market cap of $76.20 million, a price-to-earnings ratio of -0.43 and a beta of 1.38. The company has a current ratio of 13.94, a quick ratio of 13.93 and a debt-to-equity ratio of 0.15. Pliant Therapeutics has a 12 month low of $1.09 and a 12 month high of $3.46. The stock has a fifty day moving average price of $1.23 and a 200-day moving average price of $1.45.

Analyst Ratings Changes

A number of equities analysts have commented on PLRX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Pliant Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. One investment analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $3.92.

Insider Transactions at Pliant Therapeutics

In other Pliant Therapeutics news, CEO Bernard Coulie sold 89,375 shares of Pliant Therapeutics stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $1.28, for a total transaction of $114,400.00. Following the completion of the sale, the chief executive officer owned 505,601 shares of the company’s stock, valued at approximately $647,169.28. The trade was a 15.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Invesco Ltd. boosted its position in Pliant Therapeutics by 42.2% in the first quarter. Invesco Ltd. now owns 68,963 shares of the company’s stock valued at $93,000 after buying an additional 20,449 shares during the last quarter. Royal Bank of Canada raised its position in Pliant Therapeutics by 222.4% during the 1st quarter. Royal Bank of Canada now owns 362,702 shares of the company’s stock worth $491,000 after buying an additional 250,185 shares during the last quarter. AQR Capital Management LLC acquired a new stake in Pliant Therapeutics during the 1st quarter valued at approximately $97,000. Goldman Sachs Group Inc. boosted its holdings in shares of Pliant Therapeutics by 6.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 475,877 shares of the company’s stock valued at $642,000 after acquiring an additional 29,177 shares during the last quarter. Finally, Woodline Partners LP increased its stake in shares of Pliant Therapeutics by 1,875.0% in the first quarter. Woodline Partners LP now owns 2,514,084 shares of the company’s stock worth $3,394,000 after acquiring an additional 2,386,789 shares during the period. 97.30% of the stock is currently owned by hedge funds and other institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).